SPDP-SPDP-Crosslinker-DataSheet-生命科學(xué)試劑-MedChemExpress

Hotline:400-820-3792Inhibitors?ScreeningLibraries?Proteinswww.MedChemESPDPCat.No.:HY-100216CASNo.:68181-17-9Synonyms:SPDPCrosslinker分?式:C??H??N?O?S?分?量:312.36作?靶點:ADCLinker作?通路:Antibody-drugConjugate/ADCRelated儲存?式:-20°C,protectfromlight,storedundernitrogen*該產(chǎn)品在溶液狀態(tài)不穩(wěn)定，建議您現(xiàn)?現(xiàn)配，即刻使?。溶解性數(shù)據(jù)體外實驗DMSO:155mg/mL(496.22mM;Needultrasonic)MassSolvent1mg5mg10mgConcentration制備儲備液1mM3.2014mL16.0072mL32.0143mL5mM0.6403mL3.2014mL6.4029mL10mM0.3201mL1.6007mL3.2014mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲備液；該產(chǎn)品在溶液狀態(tài)不穩(wěn)定，建議您現(xiàn)?現(xiàn)配，即刻使?.體內(nèi)實驗請根據(jù)您的實驗動物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請先按照InVitro?式配制澄的儲備液，再依次添加助溶劑：(為保證實驗結(jié)果的可靠性，澄的儲備液可以根據(jù)儲存條件，適當(dāng)保存；體內(nèi)實驗的?作液，建議您現(xiàn)?現(xiàn)配，當(dāng)天使?；以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?；如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過加熱和/或超聲的?式助溶)1.請依序添加每種溶劑：10%DMSO>>40%PEG300>>5%Tween-80>>45%salineSolubility:≥2.08mg/mL(6.66mM);Clearsolution2.請依序添加每種溶劑：10%DMSO>>90%(20%SBE-β-CDinsaline)Solubility:≥2.08mg/mL(6.66mM);Clearsolution1/2MasterofBioactiveMolecules—您?邊的抑制劑?師www.MedChemEBIOLOGICALACTIVITY?物活性SPDP(SPDPCrosslinker)?種短鏈交聯(lián)劑，可通過NHS-酯和吡啶?硫醇反應(yīng)性團與半胱氨酸巰形成可降解(cleavable)的(可還原的)?硫鍵，實現(xiàn)胺與巰的結(jié)合。SPDP(SPDPCrosslinker)?種可降解(cleavable)的ADClinker，可?于合成抗體偶聯(lián)藥物(ADC)[1]。IC50&TargetDisulfideCleavableCleavable體外研究Equalamountsofanti-CD11candanti-CTLA-4Abs(inboratebufferedsaline;pH8.5)areactivatedusingSPDP.戶使?本產(chǎn)品發(fā)表的科研?獻?BioengTranslMed.26July2022.?MicrobCellFact.2021Mar10;20(1):67.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].LobedanzSetal.Aperiplasmiccoiled-coilinterfaceunderlyingTolCrecruitmentandtheassemblyofbacterialdrugeffluxpumps.ProcNatlAcadSciUSA,2007Mar13,104(11):4612-7.[2].Karumuthil-MelethilSetal.Dendriticcell-directedCTLA-4engagementduringpancreaticbetacellantigenpresentationdelaystype1diabetes.JImmunol2010Jun15,184(12):6695-708.McePdfHeightCaution:Producthasnotbeenfullyvalidatedformedicalapplications.Forresearchuseonly.Tel:400-